Evidence map›Paper›PMID 36253351›Full record

ArticlemAbs

Pandemic's silver lining.

Fortunato Ferrara, Sara D'Angelo, M Frank Erasmus, André A Teixeira, Camila Leal-Lopes, Laura P Spector, Tom Pohl, Adeline Fanni, Simon Cocklin, Andrew R M Bradbury

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Fortunato FerraraSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-4615-035X
Sara D'AngeloSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-8329-9938
M Frank ErasmusSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-8046-5048
André A TeixeiraBioscience Division, New Mexico Consortium, Los Alamos, NM, USA.ORCID 0000-0002-8348-0235
Camila Leal-LopesBioscience Division, New Mexico Consortium, Los Alamos, NM, USA.ORCID 0000-0001-7058-3350
Laura P SpectorSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-3965-9115
Tom PohlSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-8182-3249
Adeline FanniSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-7240-2792
Simon CocklinSpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-9074-741X
Andrew R M BradburySpecifica Inc., A Q2 Solutions Company, Santa Fe, NM, USA.ORCID 0000-0002-5567-8172
Q2 Solutions (United States) · USNew Mexico Consortium · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intense international focus on the COVID-19 pandemic has provided a unique opportunity to use a wide array of novel tools to carry out scientific studies on the SARS-CoV-2 virus. The value of these comparative studies extends far beyond their consequences for SARS-CoV-2, providing broad implications for health-related science. Here we specifically discuss the impacts of these comparisons on advances in vaccines, the analysis of host humoral immunity, and antibody discovery. As an extension, we also discuss potential synergies between these areas.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHumansImmunity, HumoralPandemicsAntibodies, Viralmonoclonal antibodiesSARS-CoV-2vaccines

Identifiers

PMID36253351
PMCPMC9578449
OpenAlexW4306658550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.